ChitogenX Inc.

As of October 31, 2024, ChitogenX Inc. has 83.13M shares outstanding.

These figures are as of October 31, 2024.

These figures are as of October 31, 2024. ChitogenX Inc. trades at an EV/FCF ratio of 7.18, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of October 31, 2024, ChitogenX Inc. maintains a current ratio of 0.01, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -57.50, indicating conservative leverage, while an interest coverage ratio of -1.62 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended October 31, 2024. Return on assets (ROA) is negative at -285.66, reflecting losses generated across the asset base.

As of the close on July 7, 2025, ChitogenX Inc.'s stock has declined approximately 88.89% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.01.

These figures cover the twelve months ended October 31, 2024. Free cash flow yield is negative at -36.81: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -18.04, meaning ChitogenX Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of October 31, 2024, ChitogenX Inc. has an Altman Z-Score of -368.50, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.